Tulsi Gabbard reveals US biolabs
Analysis based on 22 articles · First reported Jun 12, 2026 · Last updated Jun 15, 2026
The disclosure of US-funded biolabs and the subsequent executive order by Donald Trump to end Gain-of-Function research could impact the biotechnology and pharmaceutical industries due to increased scrutiny and potential funding restrictions. Concerns about biosecurity and ethical implications of research on dangerous pathogens may lead to stricter regulations and reduced investment in certain areas of biological research. The alleged cover-up by the United States — Presidency of Joe Biden and health officials like Anthony Fauci could erode public trust in government and health institutions, potentially affecting public health initiatives and related markets.
Director of National Intelligence Tulsi Gabbard declassified and released intelligence revealing that the United States government has funded over 120 biolabs in more than 30 countries, including Ukraine. Many of these facilities reportedly engaged in dangerous Gain-of-Function research with minimal oversight. Gabbard criticized previous administrations, including the United States — Presidency of Joe Biden, and health officials like Anthony Fauci, for allegedly covering up the existence of these labs and misleading the public. In response to these findings, President Donald Trump signed Executive Order 14292, ending federal funding for dangerous Gain-of-Function research globally. The United States — Director of National Intelligence has issued new guidance to the Intelligence Community to increase oversight and data collection on these overseas facilities, uncovering ethical, financial, and security concerns related to ongoing clinical trials.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard